Evaluation of the theranostic properties of gadolinium-based nanoparticles for head and neck cancer.
gadolinium
head and neck cancer
nanoparticles
orthotopic animal model
radiotherapy
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
02
01
2018
revised:
11
06
2018
accepted:
06
09
2018
pubmed:
15
12
2018
medline:
10
9
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
The aim of the study was to evaluate the benefits of the combination of Gadolinium-based nanoparticles AGuIX and radiotherapy on the recurrence free survival after tumor resection in a head and neck animal orthotopic model. Human head and neck CAL33 orthotopic tumors were implanted in female NMRI nude mice. The biodistribution of AGuIX was studied by fluorescence imaging. Tumor resection was performed 19 days after tumor implantation. Radiotherapy was performed 23 days after resection (10 Gy), 1 hour after AGuIX IV injection. After systemic administration, AGuIX passively accumulated in the orthotopic tumors. After tumor surgery, the combination of AGuIX with radiotherapy significantly improved the recurrence free survival and the median survival time (196 days) compared to irradiated only mice (75 days). This study demonstrated the improvement of the recurrence free survival following combination of AGuIX injection with radiotherapy after Head and neck tumor resection.
Sections du résumé
BACKGROUND
The aim of the study was to evaluate the benefits of the combination of Gadolinium-based nanoparticles AGuIX and radiotherapy on the recurrence free survival after tumor resection in a head and neck animal orthotopic model.
METHODS
Human head and neck CAL33 orthotopic tumors were implanted in female NMRI nude mice. The biodistribution of AGuIX was studied by fluorescence imaging. Tumor resection was performed 19 days after tumor implantation. Radiotherapy was performed 23 days after resection (10 Gy), 1 hour after AGuIX IV injection.
RESULTS
After systemic administration, AGuIX passively accumulated in the orthotopic tumors. After tumor surgery, the combination of AGuIX with radiotherapy significantly improved the recurrence free survival and the median survival time (196 days) compared to irradiated only mice (75 days).
CONCLUSION
This study demonstrated the improvement of the recurrence free survival following combination of AGuIX injection with radiotherapy after Head and neck tumor resection.
Substances chimiques
Radiation-Sensitizing Agents
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-410Subventions
Organisme : Fondation des gueules cassées
Pays : International
Organisme : Gueules Cassées Foundation
Pays : International
Informations de copyright
© 2018 Wiley Periodicals, Inc.